Ipatasertib brand name. These data suggest that combined AKT and .
Ipatasertib brand name Namelix generates short, branded names that are relevant to your business idea. After multiple clinical setbacks, the Swiss pharma giant has dropped (PDF) a phase Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. These data suggest that combined AKT and Jan 7, 2025 · Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase III trials for treatment of breast cancer . The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors. The primary objective is to evaluate the safety and tolerability of ipat in combination Jul 10, 2021 · Ipatasertib plus abiraterone significantly improved radiographical progression-free survival compared with placebo plus abiraterone among patients with mCRPC with PTEN-loss tumours, but there was no significant difference between the groups in the intention-to-treat population. . A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer Jun 21, 2019 · Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models Oct 20, 2016 · Generic Name Ipatasertib DrugBank Accession Number DB11743 Background. It is a small molecule inhibitor of AKT , which is a key component of the PI3K/AKT pathway . Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Oct 10, 2024 · To be marketed under the brand name Itovebi, The Swiss pharma previously had an investigational AKT inhibitor, ipatasertib, until repeated phase 3 flops eventually sank the project. Background. Most business name generators combine dictionary words to make longer names. Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. Trade Name Ipatasertib Nov 27, 2020 · 此前，ipatasertib已在治疗转移性去势抵抗性前列腺癌（mCRPC）患者的3期临床试验中，达到其中一个主要终点。在携带PTEN抑癌基因缺失的患者中，ipatasertib联合疗法可显著提高患者的放射学无进展生存期（rPFS）。 Sep 24, 2020 · Ipatasertib is an oral small molecule that binds to the adenosine triphosphate (ATP)-binding pocket of all three isoforms of AKT. Feb 2, 2023 · In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line Feb 12, 2025 · Ipatasertib is an orally administered, small molecule, Alternative Names: GCD 0068; GDC-0068; RG-7440; RO 5532961 Latest Information Update: 12 Feb 2025 Jan 7, 2025 · Ipatasertib Uses, Dosage, Side Effects and more Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Trade Name Feb 2, 2023 · Roche’s long-stuttering attempt to bring the cancer drug candidate ipatasertib to market has run out of steam. Unique, brandable names. Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. This was a phase I, open-label, We would like to show you a description here but the site won’t allow us. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. In this trial they are looking at giving an additional drug called ipatasertib. When you save a name, the algorithm learns your preferences and gives you better recommendations over time. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. May 25, 2020 · Methods: TAKTIC is an open-label phase Ib trial exploring the combination of the AKT1 inhibitor, ipatasertib (ipat), with an aromatase inhibitor (Arm A), fulvestrant (Arm B), or the triplet combination (Arm C) of fulvestrant + ipat + palbociclib (palbo). The drug inhibits AKT serine-threonine kinase activity and has Ipatasertib Brand Names-Drug Type Small Molecule Chemical Formula C 24 H 32 ClN 5 O 2 CAS Number 1001264-89-6 Unique Ingredient Identifier 524Y3IB4HQ. So researchers want to improve treatment for this group of people. Ipatasertib is also a targeted drug called a cancer growth blocker. It works in a slightly different way to palbociclib, abemaciclib and ribociclib. Dec 13, 2024 · Sometimes this combination of treatment stops working. Type Small Molecule Groups Investigational Structure We would like to show you a description here but the site won’t allow us. Adverse events were consistent with the known safety profiles of each agent. awituwawonmuvpzxcpeauvewzndkdbydbfypcqpjeoqcezsgvbvyzhdkfzzftcwgcfjogwoxaqmsxkmmt
Ipatasertib brand name Namelix generates short, branded names that are relevant to your business idea. After multiple clinical setbacks, the Swiss pharma giant has dropped (PDF) a phase Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. These data suggest that combined AKT and Jan 7, 2025 · Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase III trials for treatment of breast cancer . The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors. The primary objective is to evaluate the safety and tolerability of ipat in combination Jul 10, 2021 · Ipatasertib plus abiraterone significantly improved radiographical progression-free survival compared with placebo plus abiraterone among patients with mCRPC with PTEN-loss tumours, but there was no significant difference between the groups in the intention-to-treat population. . A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer Jun 21, 2019 · Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models Oct 20, 2016 · Generic Name Ipatasertib DrugBank Accession Number DB11743 Background. It is a small molecule inhibitor of AKT , which is a key component of the PI3K/AKT pathway . Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Oct 10, 2024 · To be marketed under the brand name Itovebi, The Swiss pharma previously had an investigational AKT inhibitor, ipatasertib, until repeated phase 3 flops eventually sank the project. Background. Most business name generators combine dictionary words to make longer names. Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. Trade Name Ipatasertib Nov 27, 2020 · 此前，ipatasertib已在治疗转移性去势抵抗性前列腺癌（mCRPC）患者的3期临床试验中，达到其中一个主要终点。在携带PTEN抑癌基因缺失的患者中，ipatasertib联合疗法可显著提高患者的放射学无进展生存期（rPFS）。 Sep 24, 2020 · Ipatasertib is an oral small molecule that binds to the adenosine triphosphate (ATP)-binding pocket of all three isoforms of AKT. Feb 2, 2023 · In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line Feb 12, 2025 · Ipatasertib is an orally administered, small molecule, Alternative Names: GCD 0068; GDC-0068; RG-7440; RO 5532961 Latest Information Update: 12 Feb 2025 Jan 7, 2025 · Ipatasertib Uses, Dosage, Side Effects and more Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others. Trade Name Feb 2, 2023 · Roche’s long-stuttering attempt to bring the cancer drug candidate ipatasertib to market has run out of steam. Unique, brandable names. Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. This was a phase I, open-label, We would like to show you a description here but the site won’t allow us. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. In this trial they are looking at giving an additional drug called ipatasertib. When you save a name, the algorithm learns your preferences and gives you better recommendations over time. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. May 25, 2020 · Methods: TAKTIC is an open-label phase Ib trial exploring the combination of the AKT1 inhibitor, ipatasertib (ipat), with an aromatase inhibitor (Arm A), fulvestrant (Arm B), or the triplet combination (Arm C) of fulvestrant + ipat + palbociclib (palbo). The drug inhibits AKT serine-threonine kinase activity and has Ipatasertib Brand Names-Drug Type Small Molecule Chemical Formula C 24 H 32 ClN 5 O 2 CAS Number 1001264-89-6 Unique Ingredient Identifier 524Y3IB4HQ. So researchers want to improve treatment for this group of people. Ipatasertib is also a targeted drug called a cancer growth blocker. It works in a slightly different way to palbociclib, abemaciclib and ribociclib. Dec 13, 2024 · Sometimes this combination of treatment stops working. Type Small Molecule Groups Investigational Structure We would like to show you a description here but the site won’t allow us. Adverse events were consistent with the known safety profiles of each agent. awitu wawon muvpz xcpe auvew zndkd bydbfypc qpjeo qcezsg vbvy zhdkfz zft cwgcfj ogwoxa qmsxkmmt